A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab

Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, constituting approximately 13% of all hematologic malignancies. Isatuximab is a monoclonal antibody targeting the CD38 protein on myeloma cells, causi...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Rishi Kumar Nanda, Jason Ta, Benjamin Tzer-Ming Chuang, Yin Mon Myat, Aishwarya Hanspal, Kyaw Zin Thein, Thura Win Htut
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Open Exploration Publishing Inc. 2025-03-01
Schriftenreihe:	Exploration of Targeted Anti-tumor Therapy
Schlagworte:	multiple myeloma isatuximab pneumonia upper respiratory tract infections (urtis) venous thromboembolism (vte) randomized controlled trials (rcts) adverse events hematologic malignancy
Online-Zugang:	https://www.explorationpub.com/uploads/Article/A1002300/1002300.pdf
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!